Regulation & law · 30/10/20261 min read
Schedules of Controlled Substances: Placement of Centanafadine in Schedule III
Summary
On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention deficit/hyperactivity disorder in adults and...
Original source language: Federal Register — Justice DepartmentOpen original release →